Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant Mammalian urate oxidase in patients with refractory gout
While 5-Amino-1MQ research remains in early stages with limited human data and no regulatory approvals, the compound has generated substantial interest in metabolic research, biohacking, and body composition optimization communities based on the compelling preclinical evidence and novel mechanism of action targeting a previously unexploited metabolic pathway
Ipamorelin Works alongside CJC-1295 to support restorative sleep, tissue repair, healthy aging, and overall vitality
While GLP1-RA have been suggested to have disease modifying properties in other autoimmune diseases such as psoriasis and psoriatic arthritis, modulating inflammatory pathways independent of their weight-reducing effects11, there is very little data on GLP1-RA in lupus
Epub 2020 Jun 23
The way we titrate GLP-1 medications helps patients do exactly that, losing between 0.5% and 1% of total body weight per week
